Avid Bioservices Inc (CDMO)

[jakedogman1]

Another thing to consider is the outlook for HALO. They just changed the trial endpoints for the phase 3 which should have a readout in mid 2019 and Roche has well as many others are ramping up other trials. The tumor micro environment is every bit as important as the primary drug treating the cancer.

AVID needs to be ready for a production increase and Lias knows it.

https://finance.yahoo.com/news/edited-transcript-halo-earnings-conference-042509225.html